Sectors
AARD
Aardvark Therapeutics, Inc.
6.10
2 x 4.50
2 x 7.28
bid
ask
+
0.31
5.35%
2 @ 07:30 PM
6.01 -0.09 (1.48%)
| Ytd | -53.54% | |
| 1y | -26.51% |
5.31
day range
6.16
3.35
52 week range
17.94
| Open | 5.70 | Prev Close | 5.79 | Low | 5.31 | High | 6.16 | Mkt Cap | 133.50M |
| Vol | 125.44K | Avg Vol | 251.06K | EPS | -3.22 | P/E | N/A | Forward P/E | N/A |
| Beta | 3.81 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 6.18 | 200-d Avg | 8.09 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 15.08M | ||
| Research and Development Expense | 10.46M | ||
| Selling, General and Administrative Expense | 4.63M | ||
| Operating Income | -15.08M | ||
| Net Income | -14.39M | ||
| Net Income Common Stock | -14.39M | ||
| Net Income Common Stock (USD) | -14.39M | ||
| Consolidated Income | -14.39M | ||
| Earnings per Basic Share | -0.66 | ||
| Earnings per Basic Share (USD) | -0.66 | ||
| Earnings per Diluted Share | -0.66 | ||
| Earning Before Interest & Taxes (EBIT) | -14.39M | ||
| Earning Before Interest & Taxes (USD) | -14.39M | ||
| Weighted Average Shares | 21.85M | ||
| Weighted Average Shares Diluted | 21.85M | ||
| Balance Sheet | |||
| Cash and Equivalents | 73.85M | ||
| Cash and Equivalents (USD) | 73.85M | ||
| Investments | 21.00K | ||
| Investments Current | 21.00K | ||
| Current Assets | 80.66M | ||
| Property, Plant & Equipment Net | 626.00K | ||
| Total Assets | 81.46M | ||
| Debt Current | 401.00K | ||
| Total Debt | 677.00K | ||
| Current Liabilities | 6.39M | ||
| Debt Non-Current | 276.00K | ||
| Total Liabilities | 6.66M | ||
| Accumulated Retained Earnings (Deficit) | -151.89M | ||
| Shareholders Equity | 74.80M | ||
| Shareholders Equity (USD) | 74.80M | ||
| Assets Non-Current | 799.00K | ||
| Total Debt (USD) | 677.00K | ||
| Liabilities Non-Current | 276.00K | ||
| Trade and Non-Trade Payables | 2.09M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 100.00K | ||
| Net Cash Flow from Financing | 262.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 11.41M | ||
| Issuance (Purchase) of Equity Shares | 262.00K | ||
| Net Cash Flow from Investing | 28.75M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 28.75M | ||
| Net Cash Flow from Operations | -17.60M | ||
| Share Based Compensation | 1.95M | ||